A composite hydrogel combining ultrashort diphenylalanine peptides with hyaluronic acid provided sustained curcumin release and promoted chronic wound healing in diabetic mice.
Self-healing injectable gelThe N-FF/HA composite hydrogel could be injected through a syringe and reform its structure, providing sustained curcumin delivery that promoted chronic diabetic wound healing in mice
What the researchers found
Diphenylalanine (FF) dipeptides modified with three different aromatic groups (benzene, naphthalene, pyrene) all formed composite hydrogels with hyaluronic acid (HA) featuring uniform distribution and good mechanical properties.
The naphthalene-modified version (N-FF/HA) showed the best performance: excellent self-healing properties (reforming after injection through a syringe), good biocompatibility with human skin fibroblast cells, and a structure of thinner nanofibers with honeycomb networks that enabled sustained curcumin release. In a streptozotocin-induced type I diabetic mouse model, curcumin-loaded N-FF/HA composite hydrogels promoted chronic wound healing significantly better than controls.
Why it matters
Diabetic foot ulcers and chronic wounds affect millions of patients worldwide and are a leading cause of amputations. Current wound care products often fail to provide sustained drug delivery in the challenging diabetic wound environment. This peptide-hyaluronic acid hydrogel addresses multiple challenges simultaneously: it's injectable (can fill irregular wound shapes), self-healing (maintains coverage), biocompatible, and provides sustained drug release. The ultrashort peptide design (just two amino acids) makes it potentially easy and inexpensive to manufacture.
How the study worked
Researchers synthesized diphenylalanine conjugated with benzene (B), naphthalene (N), and pyrene (P) aromatic moieties. These were combined with hyaluronic acid via a one-pot reaction to form composite hydrogels. The hydrogels were characterized for structure (nanofiber morphology), mechanical properties, self-healing ability, and biocompatibility using human skin fibroblast cells. Curcumin drug release kinetics were measured. In vivo wound healing was tested in a streptozotocin-induced type I diabetic mouse model.
What this study cannot tell us
The study used a type I diabetic mouse model (streptozotocin-induced), which differs from the more common type II diabetes in humans. Specific wound closure rates, healing timepoints, and statistical comparisons were not detailed in the abstract. The curcumin drug loading and release kinetics were characterized but specific values were not reported. Long-term safety and degradation products were not assessed. Human clinical translation requires further validation.
How to read the evidence
Published in ACS Applied Materials & Interfaces (a respected biomaterials journal), this study provides thorough materials characterization and preclinical in vivo validation. The combination of structural analysis, biocompatibility testing, drug release profiling, and diabetic wound model testing represents a comprehensive evaluation. However, all evidence is preclinical.
When this study was published
Published in 2021, this study contributes to the active field of peptide-based wound care biomaterials. The ultrashort peptide approach has continued to attract interest for its simplicity and scalability.
The bigger picture
Ultrashort peptides are an exciting class of biomaterials because they combine the biocompatibility of peptides with extreme simplicity of synthesis. The diphenylalanine (FF) motif is the shortest peptide known to self-assemble into nanostructures. By combining this with hyaluronic acid — itself a well-established wound healing ingredient — the researchers created a synergistic composite that is greater than the sum of its parts. This approach could be generalized to deliver various drugs for different wound types and chronic disease applications.
Questions still open
- How does the N-FF/HA hydrogel perform in type II diabetic wound models, which better represent most clinical diabetic wounds?
- Could this hydrogel platform deliver other wound-healing agents like growth factors or antimicrobial peptides alongside or instead of curcumin?
- What is the long-term fate of the peptide-hyaluronic acid hydrogel in the wound bed — does it fully degrade into safe byproducts?
Common questions
How does this injectable gel help diabetic wounds heal?
Why use such a short peptide (just two amino acids)?
Read the original research
Ultrashort Peptides and Hyaluronic Acid-Based Injectable Composite Hydrogels for Sustained Drug Release and Chronic Diabetic Wound Healing.
ACS applied materials & interfaces, 13(49), 58329-58339
Citation
Wang, Ling; Li, Jing; Xiong, Yue; Wu, Yihang; Yang, Fen; Guo, Ying; Chen, Zhaolin; Gao, Liqian; Deng, Wenbin. (2021). Ultrashort Peptides and Hyaluronic Acid-Based Injectable Composite Hydrogels for Sustained Drug Release and Chronic Diabetic Wound Healing.. ACS applied materials & interfaces, 13(49), 58329-58339. https://doi.org/10.1021/acsami.1c16738